Literature DB >> 11306862

The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III.

S Rudnik-Schöneborn1, I Hausmanowa-Petrusewicz, J Borkowska, K Zerres.   

Abstract

Proximal spinal muscular atrophy (SMA) is classified into three main subtypes (I-III), defined by age at onset and achieved motor milestones. As age at onset can be very early in SMA II and III (IIIa, onset < 3 years) and does not necessarily correlate with prognosis, the question arises whether the child can be correctly assigned to a specific SMA type at the time of presentation based on the assessment of motor function. Therefore we studied the motor milestones in 175 SMA type II and 266 SMA type III patients. In SMA II, 73% of the patients sat within the normal age range (up to 9 months), the remainder learned to do so at ages between 10 and 30 months. In SMA III, the walking milestone was passed with delay (given an upper normal limit of 18 months) in 10% of all and 16% of SMA IIIa patients (median age 13 months, range 9-53 months). There was a correlation between late sitting and walking in SMA III, since those who sat after 9 months were responsible for the majority of delayed walkers. The median age when becoming chairbound did not differ between early-onset SMA III patients who walked with delay and those who walked within the normal age range (10.2 versus 10.5 years). In conclusion, a significant proportion of patients with early-onset SMA classified as SMA II on the basis of achieved motor function turned out to be SMA III at later follow-up. It is important to reassess a child in the first 2-4 years, to determine whether walking can be achieved with or without aids, as children who start to walk late have a similar favourable outcome for ambulation compared to earlier walkers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306862     DOI: 10.1159/000052118

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  15 in total

1.  A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Thomas O Crawford; Charles Scott; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2006-06-05       Impact factor: 4.296

2.  Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Authors:  Claudia D Wurster; Petra Steinacker; René Günther; Jan C Koch; Paul Lingor; Zeljko Uzelac; Simon Witzel; Kurt Wollinsky; Benedikt Winter; Alma Osmanovic; Olivia Schreiber-Katz; Rami Al Shweiki; Albert C Ludolph; Susanne Petri; Andreas Hermann; Markus Otto
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

3.  Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.

Authors:  Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

4.  PCR-RFLP, sequencing, and quantification in molecular diagnosis of spinal muscular atrophy: limits and advantages.

Authors:  K Hamzi; H Bellayou; M Itri; S Nadifi
Journal:  J Mol Neurosci       Date:  2013-01-08       Impact factor: 3.444

5.  Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy.

Authors:  Kristin J Krosschell; Charles B Scott; Jo Anne Maczulski; Aga J Lewelt; Sandra P Reyna; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2011-06-22       Impact factor: 3.217

6.  A natural history study of late onset spinal muscular atrophy types 3b and 4.

Authors:  S Piepers; L H van den Berg; F Brugman; H Scheffer; M Ruiterkamp-Versteeg; B G van Engelen; C G Faber; M de Visser; W-L van der Pol; J H J Wokke
Journal:  J Neurol       Date:  2008-06-30       Impact factor: 4.849

Review 7.  Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies.

Authors:  Raffaella Adami; Daniele Bottai
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

Review 8.  Physical exercise training for type 3 spinal muscular atrophy.

Authors:  Bart Bartels; Jacqueline Montes; W Ludo van der Pol; Janke F de Groot
Journal:  Cochrane Database Syst Rev       Date:  2019-03-01

9.  Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial.

Authors:  Andreea Mihaela Seferian; Amélie Moraux; Aurélie Canal; Valérie Decostre; Oumar Diebate; Anne Gaëlle Le Moing; Teresa Gidaro; Nicolas Deconinck; Frauke Van Parys; Wendy Vereecke; Sylvia Wittevrongel; Mélanie Annoussamy; Michèle Mayer; Kim Maincent; Jean-Marie Cuisset; Vincent Tiffreau; Severine Denis; Virginie Jousten; Susana Quijano-Roy; Thomas Voit; Jean-Yves Hogrel; Laurent Servais
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

Review 10.  Therapeutic strategies for spinal muscular atrophy: SMN and beyond.

Authors:  Melissa Bowerman; Catherina G Becker; Rafael J Yáñez-Muñoz; Ke Ning; Matthew J A Wood; Thomas H Gillingwater; Kevin Talbot
Journal:  Dis Model Mech       Date:  2017-08-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.